Denosumab Fracture Data Positive In Prostate Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.
You may also be interested in...
Aranesp Takes A Punch; Sales Plummet 25 Percent In Fourth Quarter 2007
With ESA safety in the spotlight, Amgen faced its toughest year, CEO Sharer says.
Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio
Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.